Company news

Intensity Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

April 1, 2024

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

March 13, 2024

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

February 20, 2024

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

January 2, 2024

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

December 11, 2023

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

December 7, 2023

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

November 30, 2023

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

November 12, 2023

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

November 1, 2023

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

September 6, 2023

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

August 13, 2023

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

August 6, 2023

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

July 9, 2023

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

June 28, 2023

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

June 5, 2023

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

June 2, 2023

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

December 7, 2022

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society...

November 17, 2022

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

November 10, 2022

Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers

November 9, 2022

← Newer news releases

Calls

Decks

The 5 newest of 15 decks. Every deck is listed under its year.